|Bid||88.83 x 1100|
|Ask||103.00 x 800|
|Day's Range||88.01 - 90.30|
|52 Week Range||82.12 - 121.98|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||37.26|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PRA Health Sciences, Inc. is pleased to announce it has received an array of awards and recognition during the first months of 2019. This is the seventh consecutive year that the company has won this prestigious industry award. Clinical Researcher of the Year – The Americas is a real-world competition that recognizes the talent and passion of industry and academic researchers and is considered a key barometer of quality standards in the clinical research organization (CRO) industry.
Net new business of $664.6 million; Net book-to-bill of 1.27$722.0 million of total revenue; representing 2.9% growth at actual foreign exchange rates and 4.4% growth on a.
RALEIGH, N.C., April 09, 2019 -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its first quarter 2019 results after the market closes on Wednesday, May 1, 2019. The.
RALEIGH, N.C., April 08, 2019 -- PRA Health Sciences, Inc. is pleased to announce it has won a 2019 CRO Leadership Award in the following categories: Capabilities.
The best employers around the country are annually recognized for their commitment to developing and sustaining a culture that supports, promotes, and values its employees with the Top Workplaces Award. This year, Philadelphia Inquirer partnered with Energage, a research company that administers online surveys to employees, to honor the companies nominated in the Greater Philadelphia area. “We’re thrilled to once again be recognized as a Top Workplace,” said Samir Shah, President of Strategic Solutions.
Net new business of $667.3 million in the fourth quarter; Net book-to-bill of 1.30$729.6 million of revenue in the fourth quarter; 11.2% growth at actual foreign exchange rates.
PRA Health Sciences and the non-profit Center for Information and Study on Clinical Research Participation (CISCRP) are pleased to announce that they are collaborating to prepare and deliver Trial Results Summaries to study volunteers. A key focus for PRA is to provide a more positive overall experience for both patients and families throughout the clinical trial process. Trial Results Summaries — also called lay language summaries or plain language summaries — communicate the results of clinical trials in a format and layout that is easy to understand and accessible to patients and the public.
NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
RALEIGH, N.C., Feb. 04, 2019 -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2018 results after the market closes on Wednesday,.
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of experience and expertise to Zosano. After graduation from Yale Medical School and residency at UCSF, she was an assistant professor at UCSF in internal medicine, received her J.D. from Stanford Law School where she was an editor of Stanford Law and Policy Review before joining Wilson Sonsini Goodrich & Rosati as an associate representing Life Science companies.
BLUE BELL, Pa., Dec. 13, 2018 -- Symphony Health, a PRA Health Sciences company and a leading provider of data, cloud-based analytics and consulting solutions to life science.
PRA Health Sciences (PRA) is pleased to announce the launch of its new Pediatric Site Network (PSN). PSN is a series of key pediatric research centers around the world which will allow PRA to improve pediatric clinical development and enhance access to novel medicines for the pediatric population. PRA has formalized relationships with centers in the EU, U.S. and Israel, with plans to expand to Latin America and Asia Pacific.
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Net new business of $657.2 million; Net book-to-bill of 1.28$717.6 million of revenue; 23.3% growth at actual foreign exchange rates and 24.0% growth on a constant currency.
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / PRA Health Sciences, Inc. (NASDAQ: PRAH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 9:00 AM Eastern ...
Stock Research Monitor: PKI, PRAH, and PRPO LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...